What To Know
- Following a rigorous screening process under Horizon 2020, Filterlex’s innovative technology was selected as one of only 99 winning companies out of over 1000, from 21 countries to receive EIC funding from a total of €627 Million available.
- This EU validation will help us to further advance our technology and turn our vision into a reality to make the CAPTIS a best-in-class device for reducing the risk of stroke and other complications during catheter-based structural heart procedures such as TAVR.
Filterlex Medical, a cardiovascular medical device startup, announced today that it has been selected to receive €7 Million equity investment from the European Innovation Council Accelerator (EIC). The EIC equity investment will be a part of Filterlex’s next round of financing.
This combined funding will go towards clinical program expansion, regulatory approvals, and commercialization of the CAPTIS® full-body embolic protection system to help transform left-heart procedures.
Following a rigorous screening process under Horizon 2020, Filterlex’s innovative technology was selected as one of only 99 winning companies out of over 1000, from 21 countries to receive EIC funding from a total of €627 Million available. Entrants must meet EIC criteria for excellence, impact, and risk level, and by the time they reach the final selection stage are considered to be world-class high-impact innovations. Filterlex was also one of only 19% of companies run by a female CEO.
The EIC investment commitment follows Filterlex’s recent rapid closing of a US $6 Million series A1 investment round in November 2021. The company is also a past recipient of a €2.1 Million EU Horizon 2019 grant, which was pivotal in financing the CAPTIS first-in-human study.
Founder and CEO, Sigal Eli, said: “We are delighted to be selected to receive EIC funding for the second time. This EU validation will help us to further advance our technology and turn our vision into a reality to make the CAPTIS a best-in-class device for reducing the risk of stroke and other complications during catheter-based structural heart procedures such as TAVR.”
Filterlex is currently enrolling patients in its successfully ongoing CAPTIS first-in-human study in Israel.
